{
  "actions": [
    {
      "acted_at": "2019-02-06",
      "action_code": "10000",
      "references": [],
      "text": "Introduced in Senate",
      "type": "action"
    },
    {
      "acted_at": "2019-02-06",
      "action_code": "",
      "committees": [
        "SSHR"
      ],
      "references": [],
      "status": "REFERRED",
      "text": "Read twice and referred to the Committee on Health, Education, Labor, and Pensions.",
      "type": "referral"
    }
  ],
  "amendments": [],
  "bill_id": "s344-116",
  "bill_type": "s",
  "by_request": false,
  "committee_reports": [],
  "committees": [
    {
      "activity": [
        "referral"
      ],
      "committee": "Senate Health, Education, Labor, and Pensions",
      "committee_id": "SSHR"
    }
  ],
  "congress": "116",
  "cosponsors": [],
  "enacted_as": null,
  "history": {
    "active": false,
    "awaiting_signature": false,
    "enacted": false,
    "vetoed": false
  },
  "introduced_at": "2019-02-06",
  "number": "344",
  "official_title": "A bill to amend the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent the inter partes review process for challenging patents from diminishing competition in the pharmaceutical industry and with respect to drug innovation, and for other purposes.",
  "popular_title": null,
  "related_bills": [
    {
      "bill_id": "hr990-116",
      "identified_by": "CRS",
      "reason": "identical",
      "type": "bill"
    }
  ],
  "short_title": "Hatch-Waxman Integrity Act of 2019",
  "sponsor": {
    "bioguide_id": "T000476",
    "district": null,
    "name": "Tillis, Thomas",
    "state": "NC",
    "title": "Sen.",
    "type": "person"
  },
  "status": "REFERRED",
  "status_at": "2019-02-06",
  "subjects": [
    "Administrative remedies",
    "Drug safety, medical device, and laboratory regulation",
    "Fraud offenses and financial crimes",
    "Health",
    "Intellectual property",
    "Licensing and registrations",
    "Prescription drugs",
    "Securities"
  ],
  "subjects_top_term": "Health",
  "summary": {
    "as": "Introduced in Senate",
    "asOf": "2019-02-06",
    "date": "2021-09-10T18:21:10Z",
    "text": "Hatch-Waxman Integrity Act of 2019\n\nThis bill establishes certain limits on the filing of patent validity challenges with the Patent Trial and Appeal Board, particularly with respect to inter partes review."
  },
  "titles": [
    {
      "as": null,
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Hatch-Waxman Integrity Act of 2019",
      "type": "display"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Hatch-Waxman Integrity Act of 2019",
      "type": "short"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "A bill to amend the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent the inter partes review process for challenging patents from diminishing competition in the pharmaceutical industry and with respect to drug innovation, and for other purposes.",
      "type": "official"
    }
  ],
  "updated_at": "2022-11-01T15:32:52Z",
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/116/s/BILLSTATUS-116s344.xml"
}